Abstract Library

#4668 Predictive factors of postoperative recurrence in patients with neuroendocrine tumour of the lung: Prospective analysis of clinicopathologic features and radiomics

Introduction: In localised and locally advanced forms neuroendocrine tumours (NETs) of the lung radical surgical resection represents the standard of care, several clinicopathologic factors are potentially associated with recurrence of disease.

Conference:

Presenting Author: Paravani P

Authors: Paravani P, Russo F, Mazzilli R, Zamponi V, Mancini C,

Keywords: radiomics, predictive role, rfs, lung, lung net,

#4507 Biliary complications for metastatic patients with neuroendocrine tumours of the pancreatic head and their influence on survival: Is it necessary to change the current management?

Introduction: Neuroendocrine tumours of the pancreatic head (NETPH) can be associated with local complications. At the metastatic stage, surgery of the primary tumour (PT) is not a standard of care. But the biliary complications (BC) due to the untreated NETPH may complicate the management and deteriorate the prognosis.

Conference:

Presenting Author: Ujlaki G

Authors: Ujlaki G, Fernandez de Sevilla E, Moog S, Lamartina L, Hadoux J,

Keywords: neuroendocrine, pancreatic head, metastatic, biliary complications,

#4201 Prospective analysis of the risk of post-surgical recurrence in lung typical carcinoid

Introduction: In localized/locally advanced forms of NET, radical surgical resection represents the standard of care.

Conference:

Presenting Author:

Authors: Paravani P, Russo F, Mazzilli R, Zamponi V, Mancini C,

Keywords: Lung typical carcinoid, recurrence-free-survival, Ki-67%, Male sex, Mitotic Index, TTF-1, Surgery,

#4161 177Lu-DOTATATE (177Lu) efficacy in metastatic well-differentiated neuroendocrine tumors (wdNET): Differences in response according to metastases (met) location

Introduction: Treatment with 177Lu is standard of care for wdNET with high somatostatin receptor expression. Patterns of response could differ between hepatic (hep) and extrahepatic (ehep) met.

Conference:

Presenting Author:

Authors: Sánchez Gómez L, Guillén Sentís P, Ruffinelli J, Torrent F, Vercher Conejero J,

Keywords: 177lu-dotatate, well-differentiated neuroendocrine tumor, tumor growth rate,

#4156 Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Introduction: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET). Retrospective data suggest higher-dose SRLs may benefit patients with GEP-NET.

Conference:

Presenting Author: Singh S

Authors: Singh S, Capdevila J, Ang Chan J, de Herder W, Grozinsky-Glasberg S,

Keywords: CAM2029, GEP-NET, high plasma exposure, octreotide, randomised active-controlled, somatostatin receptor ligands, SORENTO,